Combination therapy of continuous arterial infusion of nafamostat mesilate and arterial injection of human urinary trypsin inhibitor (ulinastatin) for severe acute pancreatitis

Therapeutic Research

Volumn 23, Issue 6, 2002, Pages 1265-1275

  Hara, Ayumi ^a   Arai, Jun ^a   Matsukawa, Hidehiko ^a   Inoue, Nagamu ^a   Ogata, Haruhiko ^a   Iwao, Yasushi ^a   Yoshioka, Masahiro ^a   Hibi, Toshifumi ^a  

^a Hara Clinic   (Japan)

Author keywords

Continuous arterial infusion; Cytokine; Human urinary trypsin inhibitor; Nafamostat mesilate; Severe acute pancreatitis; Ulinastatin

Indexed keywords

CYTOKINE; INTERLEUKIN 6; LEUKOCYTE ELASTASE; NAFAMSTAT MESILATE; TUMOR NECROSIS FACTOR ALPHA; ULINASTATIN;

ACUTE PANCREATITIS; ADULT; ARTERY CATHETER; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEVICE; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; ENZYME INHIBITION; HUMAN; MALE; PAIN; SYMPTOM;

EID: 0036033484     PISSN: 02898020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Takeda K, Kumagai Y, Kobari M, Matsuno S. Continuous arterial infusion of protease inhibitor for severe acute pancreatitis. Gastroenterol Jpn 1989;24:340 (Rapid Communication).
2. Hara A, Ito T, Yoshioka M, et al. A case of severe acute pancreatitis successfully treated by continuous arterial infusion of a protease inhibitor. Jpn J Gastroenterol 1994;91:2021-5 (Japanese).
3. Yoshida M, Takada T, Yasuda H, et al. Severe acute necrotizing pancreatitis treated by continuous regional arterial infusion of a protease inhibitor and antibiotics by the double-catheter method-Case report. Jpn J Pancreas 1999;14:143-9 (Japanese with English Abstract).
4. Kakugawa Y, Takeda K, Kobori M, Matsuno S. Effect of arterial infusion of protease inhibitor on experimental acute pancreatitis. Gastroenterol Jpn 1989;24:95 (Rapid Communication).
5. Takeda K, Matsuno S, Suemura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg 1996;171:394-8.
6. Ogawa M, Nishibe S, Mori T, Neumann S. Effect of human urinary trypsin inhibitor on granulocyte elastase activity. Res Commun Chem Pathol Pharmacol 1987;55:271-4.
7. Horiuchi A, Iwatsuki K, Yonekura H, Ren LM, Chiba S. Gabexate and camostat, synthetic proteinase inhibitors, as direct inducing factors of water and bicarbonate secretion in the isolated and blood-perfused dog pancreas. J Pharmacol Exp Ther 1990;252:320-6.
8. Matsukawa H, Hara A, Ito H, et al. Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis: Clinical effect of arterial injection of ulinastatin. Jpn J Gastroenterol 1998;95:1229-34 (Japanese with English Abstract).
9. Asakura H, Hibi T, Tanaka T, et al. Reevaluation of selective intraarterial predonisolone injection therapy in ulcerative colitis. Jpn J Gastroenterol 1978;75:818-25 (Japanese with English Abstract).
10. Yagita A, Tatekawa I. Combined intraarterial injection therapy with steroid and ulinastatin for Crohn's disease and ulcerative colitis at their active stage. Progress Med 1987;142:936-7 (Japanese with English Abstract).
11. Chang YC, Tsang YM, Kung KL, et al. Transcatheter control of intractible gastrointestinal bleeding. J Forsman Med Assoc 1991;90:81-7.
12. Imrie CW, Benjamin IS, Ferguson JC, et al. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg 1978;65:337-41.
13. Frey CF, Bradley EL, Beger HG. Progress in acute pancreatitis. Surg Gynecol Obste 1985;202: 408-17.
14. Okumura Y, Inoue H, Fujiyama Y, Bamba T. Effects of serine protease inhibitors on accumulation of polymorphonuclear leukocytes in the lung induced by acute pancreatitis in rats. J Gastroenterol 1995;30:379-86.
15. Beuer J, Reich Z. Uber die antitypsche wirkung des harns. Med Klin 1909;46:1744-7.
16. Hochstrasser K, Bretzel G, Feuth H, Hilla W, Lempart K. The inter-alpha-trypsin inhibitor as precursor of the acid-stable proteinase inhibitors in human serum and urine. Hoppe-Seyer's Z Phisiol Chem 1976;357:153-62.
17. Hochstrasser K, Schonberger OL, Rossmanith I, Wachter E. Kunitz-type proteinase inhibitors derived by limited proteolysis of the inter-alpha-trypsin inhibitor: V. Attachments of carbohydrates in the human urinary trypsin inhibitor isolated by affinity chromatography. Hoppe-Seyer's Z Phisiol Chem 1981;362:1357-62.
18. Sumi H, Takada Y, Takada A. Studies on human urinary trypsin inhibitor: Its modification on treatment of urine and acid. Thomb Res 1977;11:747-54.
19. Tanaka Y, Maehara S, Sumi H, Toki N, Moriyama S, Sasaki K. Purification and partial characterization of two forms of urinary trypsin inhibitor. Biochem Biophys Acta 1982;705:192-9.
20. Kaumeyer JF, Polazzi JO, Kotick MP. The mRNA for a proteinase inhibitor related to the HI-30 domain of inter-alpha-trypsin inhibitor also encodes α 1-microglobulin (protein HC). Nucl Acid Res 1986;14:7839-50.
21. Hirose J, Ozawa T, Miura T, et al. Human neutrophil elastase degradates inter-alpha-trypsin inhibitor to liberate urinary trypsin inhibitor related proteins. Biol Pharm Bull 1998;21:651-6.
22. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320:365-76.
23. Kato K, Arai J, Sakai K. Human urinary trypsin inhibitor: Its structure, biochemical property and biosynthesis. Med Pharmachol 1995;33:1089-97 (Japanese with English Abstract).
24. Kato K, Nagao Y, Kurosawa M. Effect of human urinary trypsin inhibitor (ulinastatin) on inflammatory mediators from leukocytes: Possible role in the prevention of SIRS. Med Pharmachol 1995;34:499-506 (Japanese with English Abstract).
25. Faarvang HJ. Urinary trypsin inhibitor in man ("Mingin"). Scand J Clin Invest 1965;17 (Suppl 83):1-78.
26. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-53.
27. Ohnishi H, Suzuki K, Niho T, Ito C, Yamaguchi K. Protective effects of urinary trypsin inhibitor in experimental shock. Jpn J Pharmachol 1985;39:137-44.
28. Ohnishi H, Kosuzume H, Ashida Y, Kato K, Honjo I. Effects of urinary trypsin inhibitor on pancreatic enzymes and experimental pancreatitis. Digest Dis Sciences 1984;29:26-32.
29. Uhl W, Buchler M, Malfertheiner P, Martini M, Beger HG. PMN-elastase in comparison with CRP, antiproteases, and LDH as indicators of necrosis in human acute pancreatitis. Pancreas 1991;6:253-9.
30. Leser HG, Gross V, Scheibenbogen C, et al. Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. Gastroenterology 1991;101:782-5.
31. Sameshima H, Ikei S, Mori K, et al. The role of tumor necrosis factor-α in the aggravation of cerulein-induced pancreatitis in rat. Int J Pancreatol 1993; 14:107-15.
32. Ranson JHC, Spencer FC. The role of peritoneal ravage in severe pancreatitis. Ann Surg 1978; 187:565-75.
33. Larvin M, Chalmers AG, Robinson PJ, McMahon MJ. Debridement and closed cavity irrigation for treatment of pancreatic necrosis. Br J Surg 1989;76:465-71.